TEL AVIV - Chemomab Therapeutics Ltd. (NASDAQ:CMMB), a clinical stage biotechnology company, announced today that it has been granted a new patent by the European Patent Office for its monoclonal antibody CM-101, used in treating various liver diseases, including Primary Sclerosing Cholangitis (PSC).
This grant further strengthens the company's intellectual property portfolio in Europe and complements existing patents in the United States, Israel, China, and other significant markets.
The newly issued European patent specifically covers the use of CM-101 and related anti-CCL24 antibodies for liver diseases. CM-101, which is currently undergoing a global Phase 2 SPRING trial for PSC, has completed patient enrollment, with results expected to be announced by mid-2024. PSC is a severe condition with no FDA-approved treatments to date, often leading to liver transplantation.
CM-101 targets CCL24, a protein implicated in fibrosis and inflammation, and has shown promise in inhibiting fibrogenesis and disrupting core pathways of PSC.
This dual mechanism of action sets CM-101 apart from other drugs in development for PSC. The medication has already been granted Orphan Drug designation in both the U.S. and the E.U., and the FDA has awarded CM-101 Fast Track designation for PSC treatment in adults.
Chemomab's CEO and Chief Scientific Officer, Dr. Adi Mor, highlighted the significance of the patent grant as the company prepares for the midyear release of the Phase 2 PSC trial data, which may provide the first substantial clinical proof-of-concept of CM-101's therapeutic activity.
The protection afforded by this and other patents is anticipated to extend until 2038, potentially extending up to five years upon market approval. CM-101 has been validated as a therapeutic target in extensive clinical and nonclinical studies, demonstrating safety and tolerability in earlier clinical trials.
As Chemomab advances its research, the biotech industry and investors are watching closely for the midyear topline data from the ongoing Phase 2 PSC trial, which could mark a pivotal moment for the company. This news is based on a press release statement from Chemomab Therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.